Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Miki, Kiyota"'
Autor:
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino
Publikováno v:
Leukemia Research Reports, Vol 20, Iss , Pp 100395- (2023)
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnos
Externí odkaz:
https://doaj.org/article/82b016d7b6d64623a8db970348a6c492
Autor:
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple my
Externí odkaz:
https://doaj.org/article/bdff3f7ce0164c809dccfaff7fdd38f3
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms. Despite recent improvement in the treatment outcome of multiple myeloma by novel molecular-targeted chemotherapeutics, multiple myeloma remains incur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0a936df6271f349bf451e73ad0bd1e
https://doi.org/10.1158/1535-7163.c.6535282
https://doi.org/10.1158/1535-7163.c.6535282
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 62K, Chromosomal abnormalities and signaling molecule expression in myeloma-derived cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11deddfc12514842deb3f6aaaec838c3
https://doi.org/10.1158/1535-7163.22496473
https://doi.org/10.1158/1535-7163.22496473
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 141K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b19f0202eb224641e587fe3cde47af9
https://doi.org/10.1158/1535-7163.22496476.v1
https://doi.org/10.1158/1535-7163.22496476.v1
Autor:
Masafumi Taniwaki, Shinsuke Iida, Yukimasa Shiotsu, Shigeo Horiike, Yosuke Matsumoto, Natsumi Sakamoto, Yoshiaki Chinen, Shinsuke Mizutani, Ryuko Nakayama, Miki Kiyota, Tsutomu Kobayashi, Mio Yamamoto-Sugitani, Hisao Nagoshi, Masaki Ri, Junya Kuroda, Yuji Shimura
PDF file - 75K, Clinical information for patient-derived primary myeloma cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8b5408b5eca5f35cfdcde9da6f48b8
https://doi.org/10.1158/1535-7163.22496470.v1
https://doi.org/10.1158/1535-7163.22496470.v1
Autor:
Masafumi Taniwaki, Shinsuke Iida, Shigeo Horiike, Yosuke Matsumoto, Tsutomu Kobayashi, Eri Kawata, Masaki Ri, Natsumi Sakamoto, Shinsuke Mizutani, Mio Yamamoto-Sugitani, Miki Kiyota, Hisao Nagoshi, Yuji Shimura, Junya Kuroda, Yoshiaki Chinen
Supplementary Figure S3. AMO-1 cells and NCI-H929 cells were co-cultured with HS-5 cells for 48 hours, and then were treated by BX-912 at its IC50s for 3 hours. The activities of PDPK1Ser241, RSK2Ser227 and AKTThr308 were examined by Western blotting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d698c1c9ac8609727fc355be956c03
https://doi.org/10.1158/0008-5472.22403810.v1
https://doi.org/10.1158/0008-5472.22403810.v1
Autor:
Masafumi Taniwaki, Shinsuke Iida, Shigeo Horiike, Yosuke Matsumoto, Tsutomu Kobayashi, Eri Kawata, Masaki Ri, Natsumi Sakamoto, Shinsuke Mizutani, Mio Yamamoto-Sugitani, Miki Kiyota, Hisao Nagoshi, Yuji Shimura, Junya Kuroda, Yoshiaki Chinen
Supplemental Methods and Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eaae08f3dce9a4e708043d17bed81f8
https://doi.org/10.1158/0008-5472.22403819.v1
https://doi.org/10.1158/0008-5472.22403819.v1
Autor:
Masafumi Taniwaki, Shinsuke Iida, Shigeo Horiike, Yosuke Matsumoto, Tsutomu Kobayashi, Eri Kawata, Masaki Ri, Natsumi Sakamoto, Shinsuke Mizutani, Mio Yamamoto-Sugitani, Miki Kiyota, Hisao Nagoshi, Yuji Shimura, Junya Kuroda, Yoshiaki Chinen
Supplementary Table S1. Clinical information of patients whose myeloma cells were subjected to Western blotting and in vitro treatment with BX-912.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c94ad1bd9770a7b0b8519d52a952958
https://doi.org/10.1158/0008-5472.22403804
https://doi.org/10.1158/0008-5472.22403804
Autor:
Itaru Matsumura, Junya Kuroda, Junya Kanda, Shosaku Nomura, Yuji Shimura, Nobuhiko Uoshima, Jun Ishikawa, Katsuya Wada, Masayuki Hino, Yuzuru Kanakura, Yutaka Shimazu, Hitomi Kaneko, Akifumi Takaori-Kondo, Kansai Myeloma Forum Investigators, Tomoki Ito, Chihiro Shimazaki, Yoshiyuki Onda, Satoru Kosugi, Toru Kida, Ryosuke Yamamura, Shin-ichi Fuchida, Hirohiko Shibayama, Takae Kohara, Satoshi Yoshihara, Aya Nakaya, Miki Kiyota, Hideo Yagi, Kensuke Ohta, Kazunori Imada, Hirokazu Tanaka
Publikováno v:
International Journal of Hematology. 112:435-438
We retrospectively analyzed the clinical features and outcomes in a real-world cohort of adolescents and the young adult (AYA) patients (age between 16 and 39 years) with symptomatic multiple myeloma (MM) registered with the Kansai Myeloma Forum. 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c49f3efca089c372ecde178c5e6fcd
https://doi.org/10.1007/s12185-020-02996-6
https://doi.org/10.1007/s12185-020-02996-6